Hepatocyte growth factor receptor (HGFR or Met) upregulation has been proven to play important roles in
non-small cell lung carcinoma (NSCLC). Interestingly, chemoresistance against
epidermal growth factor receptor (EGFR) inhibitors including
erlotinib and
gefitinib was also related to Met. Targeting bromodomain and extra terminal domain (BET)
proteins, especially BRD4, has shown inhibitory effects on
lung cancer, but the mechanism is unclear. Herein, we found that JQ1 (BET inhibitor) suppressed NSCLC cell growth, reduced the Met expression, and contributed to inactivation of PI3K/Akt and MAPK/ERK pathways. Moreover, another BET
protein inhibitor
I-BET151, or BRD4 depletion, also inhibited NSCLC cell growth and downregulated Met. JQ1 inhibited HGF-induced cell growth and Met/PI3K/Akt activation, also inhibited A549
tumor growth in xenograft mouse models, in parallel with Met downregulation. Moreover, JQ1 inhibited the growth of paired
erlotinib-sensitive and resistant HCC827 cells in parallel with Met downregulation and PI3K/Akt signaling inactivation. JQ1 also exerted inhibitory influences on the growth of
erlotinib-sensitive and resistant HCC827
tumors in xenograft mouse models. These results suggested that targeting BET
proteins inhibited NSCLC via downregulating Met and inactivating PI3K/AKT pathway. Our findings reveal a novel mechanism of BET
proteins implicated in NSCLC progression with Met taken into consideration.